MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 180 Publications

19 Customer Reviews

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

  • The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

    Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

  • VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

    Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

  • Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

    IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

  • Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

    Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

  • A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

    Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.
Targets
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
In vitro

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 M3zFUmN6fG:2b4jpZ{BCe3OjeR?= NGDU[og{KM7:TR?= MXy3NkBp NXrQZmo1TE2VTx?= MWnJcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? MnO3NlA2PzFyNkm=
A431 NGTCS5BMcW6jc3WgRZN{[Xl? Ml;0OUDPxE1? MmjpOUBp NGOyenVFVVOR MU\TeZBxemW|c3XzJJRp\SC|aXfuZYxqdmdib3[gRYt1KGGwZDDFdos> MX:yNFU4OTB4OR?=
HepG2 MVvDfZRwfG:6aXOgRZN{[Xl? MX:xNEDPxE1? NVTsUFJ1OjRiaB?= M{e4b2ROW09? MVvT[Y5{cXSrenXzJJJme2m|dHHueEBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDzc5Ji\mWwaXK= NYPicG1VOjF{MEW5NlU>
Sk-Hep1 MXXDfZRwfG:6aXOgRZN{[Xl? NXjZN5JOOTBizszN NGDVVIMzPCCq MmW4SG1UVw>? MUXT[Y5{cXSrenXzJJJme2m|dHHueEBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDzc5Ji\mWwaXK= NXfPWWVXOjF{MEW5NlU>
OCUT1 cells harbored PIK3CA (H1047R+/+) NXroT3lyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofrN{DPxE1? MYi1JIQ> M{DobWROW09? NF\NXnFKSzVyPUCuNVQh|ryP M1vudlIyOjh7Mk[3
K1 cells harbored PIK3CA (E542K+/+) MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVyzJO69VQ>? Mor2OUBl NFXJVWRFVVOR MVXJR|UxRTBwNUKg{txO NHP4NlIzOTJ6OUK2Oy=>
FTC133 cells harbored PTEN (allele deletion and R130+) MonjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:zJO69VQ>? MkHyOUBl M3GzN2ROW09? NFHwWFNKSzVyPUCuNVgh|ryP NUftVW1yOjF{OEmyOlc>
C643 cells harbored HRAS (G13R+/−) M4Kzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O5SlMh|ryP M3;qT|Uh\A>? M{K5[GROW09? NGrySoxKSzVyPUCuNlch|ryP NU\1XFVpOjF{OEmyOlc>
Hth7 cells harbored NRAS (Q61R+/−) M1vCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fGUlMh|ryP MoLNOUBl NXHkVG1CTE2VTx?= M{DFWGlEPTB;ND61JO69VQ>? M2jWRVIyOjh7Mk[3
TPC1 cells harbored RET/PTC1 rearrangement NFrzSodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWqzJO69VQ>? MknEOUBl NUTud2s5TE2VTx?= NF\EZ3VKSzVyPUCuOVkh|ryP MUWyNVI5QTJ4Nx?=
Hth74 NUW3cZNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTEN{DPxE1? NVn2R2FFPSCm NYPPVmZqTE2VTx?= MnHGTWM2OD1{LkG5JO69VQ>? MWCyNVI5QTJ4Nx?=
KAT18 NXH5WnpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnOSW9sOyEQvF2= MXu1JIQ> MXvEUXNQ M3PKTmlEPTB;ND62NkDPxE1? NH7tepIzOTJ6OUK2Oy=>
SW1736 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXlNVAxKM7:TR?= NELqVIE2KGR? M{n2UWROW09? M2rWTWlEPTB;NEeuOVYh|ryP NHHFWYUzOTJ6OUK2Oy=>
WRO NUm5R5NyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPINVAxOCEQvF2= MmPaOUBl MUTEUXNQ MlvZTWM2OD5zMECwJO69VQ>? NXnkXXRSOjF{OEmyOlc>
TAD2 NXnhdo54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rEZ|ExODBizszN M3;PWFUh\A>? M3jjV2ROW09? M2m0RWlEPTB-MUCwNEDPxE1? M4[5fVIyOjh7Mk[3
LN229 MUXBdI9xfG:|aYOgRZN{[Xl? MY[wMlUh|ryP NFG4O5I3OCCq NEHzTYdFVVOR NUjEXndsSXWpbXXueJMh[XCxcITv[4VvcWNiZX\m[YN1eyCxZjDn[YZqfGmwaXK= MnTvNlIxPTd7MUS=
T98G M1L4U2Fxd3C2b4Ppd{BCe3OjeR?= NEDjSpcxNjVizszN MnnMOlAhcA>? MnPZSG1UVw>? MmS4RZVodWWwdIOgZZBweHSxZ3XubYMh\W[oZXP0d{Bw\iCpZX\peIlvcWJ? NV7PNYVHOjJyNUe5NVQ>
HC11 NELt[oJHfW6ldHnvckBCe3OjeR?= NILBfW4yOCEQvF2= MlS2NlQhcA>? M1\remROW09? M1\TVWlvcGmkaYTzJO6zNWOjc3XpckBidmRiQVTSVEB{gW62aHXzbZM> MUKyNlQzPjZ{MR?=
MOLT-4 NX3WVGFIS3m2b4TvfIlkKEG|c3H5 M3;2NlExKM7:TR?= MY[0PEBp M3fydmROW09? MVnJR|UxRTFwN,MAje69VQ>? MVOyNlYyPDJ2Mx?=
CEM-R MVTDfZRwfG:6aXOgRZN{[Xl? Moi3NVAh|ryP M1vWO|Q5KGh? NIS5cWRFVVOR MX\JR|UxRTNwM,MAje69VQ>? NYXx[I1jOjJ4MUSyOFM>
CEM-S MVjDfZRwfG:6aXOgRZN{[Xl? M{S4PVExKM7:TR?= NHL0fYY1QCCq M1viO2ROW09? MnTpTWM2OD13LkJihKnPxE1? NUPW[nlxOjJ4MUSyOFM>
MOLT-4 MVvGeY5kfGmxbjDBd5NigQ>? NHi2O4IyOCEQvF2= M4H5bVI1KGh? NEnDXHdFVVOR MlKyRoxw[2u|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\SCxZjD0bIUh[2WubDDjfYNt\Q>? NXP0O4hbOjJ4MUSyOFM>
MOLT-4 MWDGeY5kfGmxbjDBd5NigQ>? NXzuNpZ7POLCid88US=> NFfZU4c1KGh? MlLESG1UVw>? NIPScJFKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDN2EwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ? M1W5UFIzPjF2MkSz
CEM-R MX;GeY5kfGmxbjDBd5NigQ>? MonpOQKBkc7:TR?= NUW4fJc3PCCq NWm0dVAyTE2VTx?= MlH4TY5kemWjc3XzJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CCOQ{TBM2ItKGFid3XscE1me3SjYnzpd4hm\CCjdYTvdIhi\3libXHyb4Vz NGXtUW8zOjZzNEK0Ny=>
CEM-S M17NeGZ2dmO2aX;uJGF{e2G7 NYrZVYFYPOLCid88US=> NHX5WG41KGh? M3nSZ2ROW09? MVnJcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFNVGvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI> NEDHdYEzOjZzNEK0Ny=>
HepG2 cell MUDLbY5ie2ViQYPzZZk> NVPwdlVjOjBizszN NGDCWpgzPCCq NVfJbmU5TE2VTx?= Mlm5SI94dnKnZ4XsZZRmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? NFzjUYEzOzd7N{OxPS=>
HepG2 cell MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHqN|Ah|ryP NXS2dWJNOjRiaB?= M4nUTGROW09? NYC1U3FCUW6qaXLpeJMh[2WubDDndo94fGh? MojONlM4QTd|MUm=
HepG2 cell MkPORZBweHSxc3nzJGF{e2G7 MkTLNlAh|ryP MorONlQhcA>? NEHBd|hFVVOR Mn3qTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NUCxTGlwOjN5OUezNVk>
GEO MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWO1NFAhdk1? MV:3NkBp NIDneo5FVVOR Mk\RTY5pcWKrdIOgZ4VtdCCpcn;3eIg> M4XpN|I1PThzMkOx
CNE-1 NYHLV2NKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfwTG1POTBizszN NFzm[HA6PiCq NGP3OJdFVVOR NYLZfm9DUUN3ME2yMlk3KM7:TR?= M3;F[lI2OzN4OUK1
CNE-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T4SFExKM7:TR?= M4H2Z|k3KGh? NYXqNXo6TE2VTx?= MX7JR|UxRTRwNUOg{txO NWX0T4pbOjV|M{[5NlU>
HONE-1 NX30c49MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3FOWMyOCEQvF2= NYLpNFF5QTZiaB?= Mn3ZSG1UVw>? MnzWTWM2OD1|LkO3JO69VQ>? NV7HRnRzOjV|M{[5NlU>
SUNE-1 MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzWenMyOCEQvF2= MX25OkBp M4jEemROW09? M2nKeWlEPTB;MD61NkDPxE1? NGHn[oszPTN|NkmyOS=>
CNE-2 M4\rcGZ2dmO2aX;uJGF{e2G7 NHK2O20yOCEQvF2= M4ixZlQ5KGh? NEjsXINFVVOR M3LGNWlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhTzF? NYi2[XNEOjV|M{[5NlU>
HONE-1 MojzSpVv[3Srb36gRZN{[Xl? NF[5e2EyOCEQvF2= M4TIPVQ5KGh? MnO2SG1UVw>? MmnwTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBIOQ>? NF[5XpozPTN|NkmyOS=>
NEC8 NWn6doZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPCS|ZKSzVyPUCuNFk3PTFizszN NFL0[I5USU6JRWK=
P12-ICHIKAWA NFq1NXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;DV2NKSzVyPUCuNVE3OiEQvF2= M1voTnNCVkeHUh?=
MDA-MB-175-VII M2T4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrh[IxMUUN3ME2wMlE{PzN6IN88US=> M4LhdnNCVkeHUh?=
AsPC-1 M4jvc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMkKxNlIh|ryP MULTRW5ITVJ?
T47D M1\NXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMkiyOUDPxE1? NI\G[nhUSU6JRWK=
HH MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwM{CyPFMh|ryP NX\aXFJ5W0GQR1XS
MOLT-16 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;0TWM2OD1yLkOwN|Ih|ryP NGXvVINUSU6JRWK=
ES5 NF3MUoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rIRmlEPTB;MD6zOFQ2PSEQvF2= MV7TRW5ITVJ?
RS4-11 MlPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3r1XGlEPTB;MD6zOFYyKM7:TR?= Mo\nV2FPT0WU
KARPAS-45 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmezTWM2OD1yLkO3N|IyKM7:TR?= MkHiV2FPT0WU
NCI-H720 MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17hdmlEPTB;MD6zO|Y4QSEQvF2= MkOwV2FPT0WU
H9 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnqWGxPUUN3ME2wMlM5QDh|IN88US=> MlrlV2FPT0WU
EFM-19 MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjtUFdKSzVyPUCuOFQxOSEQvF2= MYHTRW5ITVJ?
SBC-1 NFfzXoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:xZWlEPTB;MD60OFA{PSEQvF2= MWTTRW5ITVJ?
A4-Fuk NV\GR5BtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX0NGhKSzVyPUCuOFY5PjhizszN NWXQZZloW0GQR1XS
NCI-H1563 Mn7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2m2V2lEPTB;MD60PFE5QSEQvF2= NVvvbI5tW0GQR1XS
HCC1419 MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTqTWM2OD1yLkS4PFkzKM7:TR?= M4D2XnNCVkeHUh?=
H-EMC-SS MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fnO2lEPTB;MD60PVk{QSEQvF2= M3rLcXNCVkeHUh?=
BHT-101 NX3HOodPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;6dYZKSzVyPUCuOVI6PjFizszN NGT2fHZUSU6JRWK=
IGROV-1 M3rLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnu1TWM2OD1yLkW1NlQ6KM7:TR?= MVnTRW5ITVJ?
HGC-27 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrxO2pKSzVyPUCuOVY4QDNizszN Ml7qV2FPT0WU
MDA-MB-361 NXTFSWhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwNUe3OlEh|ryP M3:4NHNCVkeHUh?=
KE-37 NVHFSmpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwNUiyOkDPxE1? Mk\2V2FPT0WU
HCC70 NEDsfIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPPTWM2OD1yLkW5PFI4KM7:TR?= Mmr4V2FPT0WU
LNCaP-Clone-FGC MlzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwNkGwOFgh|ryP MVvTRW5ITVJ?
HAL-01 NWL0cm9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrPPW1KSzVyPUCuOlIyOyEQvF2= NFvvd3JUSU6JRWK=
HT M2LZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDaTWM2OD1yLk[zNlM6KM7:TR?= NWHpW2FtW0GQR1XS
MDA-MB-415 NFHYTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwNkO2NlYh|ryP NWfYfJJTW0GQR1XS
NOS-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHERWFKSzVyPUCuOlM4OjNizszN Mnr6V2FPT0WU
DU-145 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwNkS3OFUh|ryP MnHiV2FPT0WU
OCUB-M M1TmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwN{C5OlYh|ryP M{X0TXNCVkeHUh?=
VA-ES-BJ NIG2c|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwN{OwNlUh|ryP M4DmWnNCVkeHUh?=
J-RT3-T3-5 NVjj[XVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwN{S0NFMh|ryP NEmzTnpUSU6JRWK=
MOLT-4 NEj0eldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFW2[opKSzVyPUCuPFA2QDJizszN MWfTRW5ITVJ?
NB7 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfld|dKSzVyPUCuPFI1OTFizszN MoHTV2FPT0WU
L-363 NHzqWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwOEO0OFIh|ryP NWrSVWlzW0GQR1XS
NKM-1 NFvLXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwOE[yOVMh|ryP NIHW[4dUSU6JRWK=
HOP-92 NFSy[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwOEeyNlMh|ryP NEXYdItUSU6JRWK=
OAW-42 NGO4R4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorpTWM2OD1yLki4O|Ih|ryP NWrQXm9pW0GQR1XS
HuO9 MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1e0emlEPTB;MD65Nlc2OSEQvF2= NI\Bb4hUSU6JRWK=
MFE-280 NXLGWJhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwOU[0OlUh|ryP Ml\jV2FPT0WU
EM-2 MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwOUe5N|kh|ryP NVzEW5RpW0GQR1XS
NCI-H520 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnpPW5EUUN3ME2wMlk5PTl{IN88US=> NW\sem5KW0GQR1XS
LB2241-RCC NW\NZmJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zUeGlEPTB;MD65PVc{PCEQvF2= M1P4N3NCVkeHUh?=
SK-NEP-1 NVnLNFdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHYS5RKSzVyPUGuNVQ1QDVizszN MYTTRW5ITVJ?
LXF-289 NF;Q[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr3T45KSzVyPUGuNVcyPTZizszN NFvj[5NUSU6JRWK=
EPLC-272H NWrvSm9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTFwMUeyOVYh|ryP MYjTRW5ITVJ?
COLO-684 NXT3ZnVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moe5TWM2OD1zLkKzO|I2KM7:TR?= MWfTRW5ITVJ?
ES1 NULrR2FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXmw[|dZUUN3ME2xMlI1ODZ3IN88US=> Mn\zV2FPT0WU
DOHH-2 NFG2cIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPPcYNKSzVyPUGuNlgzODNizszN MVzTRW5ITVJ?
CTB-1 M3vuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr1R3Q2UUN3ME2xMlI5QTlizszN NGDsb5NUSU6JRWK=
G-401 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfGWFBuUUN3ME2xMlI6Pzl3IN88US=> MkfvV2FPT0WU
LoVo M2LGWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrCeXBKSzVyPUGuN|I2OzRizszN M33CTHNCVkeHUh?=
Ramos-2G6-4C10 NF31dYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjDbYRKSzVyPUGuN|M4ODFizszN M1\5WnNCVkeHUh?=
MFM-223 MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTFwM{S0OlEh|ryP NVq2TWF3W0GQR1XS
PA-1 NFHONG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoraTWM2OD1zLkO1NlY2KM7:TR?= NF\xcW9USU6JRWK=
697 MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPsT|hKSzVyPUGuN|c3OTZizszN M{S5dXNCVkeHUh?=
QIMR-WIL NU\ZelY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFOwcIJKSzVyPUGuOFkyOTZizszN MV7TRW5ITVJ?
HOS MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlu3TWM2OD1zLkS5OVU5KM7:TR?= NUizT4k3W0GQR1XS
DMS-273 MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXZNY9EUUN3ME2xMlUyQTV7IN88US=> Ml\HV2FPT0WU
ME-180 NIjhWpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFwNU[4PVEh|ryP Ml7FV2FPT0WU
HCC2218 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGC2ellKSzVyPUGuOlgzOjVizszN MVjTRW5ITVJ?
CAL-54 M{LKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrRWHAyUUN3ME2xMlcyOjR{IN88US=> NXjVfFhiW0GQR1XS
OMC-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFwN{S2O|ch|ryP NU\hcmptW0GQR1XS
COR-L105 MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjw[VNKSzVyPUGuO|k4OzdizszN NHXIeYVUSU6JRWK=
BV-173 NV60e3dQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmmzTWM2OD1zLkixNFc1KM7:TR?= NXzEfZNGW0GQR1XS
RKO MlO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XWU2lEPTB;MT64O|ExOSEQvF2= MYnTRW5ITVJ?
SNU-387 NHWzUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\YNWlEPTB;MT64PFQxPiEQvF2= NFr2TWpUSU6JRWK=
SW1088 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLsVo1vUUN3ME2xMlk1PjB4IN88US=> M1i1PHNCVkeHUh?=
Hs-578-T M3vDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJwMUG0N|Mh|ryP M{DRO3NCVkeHUh?=
OC-314 NFKzTlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHW5NodKSzVyPUKuNVUxQDZizszN NVvq[WlMW0GQR1XS
RMG-I M{\TPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJwMU[zPVgh|ryP NF24RXVUSU6JRWK=
NCI-H1395 Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHwc5hKSzVyPUKuNVgxQTFizszN MlnOV2FPT0WU
GAMG MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLkfWZ{UUN3ME2yMlI{QDR3IN88US=> MYnTRW5ITVJ?
LB1047-RCC M1e4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvnSVlxUUN3ME2yMlI1OzF5IN88US=> NGGwb4FUSU6JRWK=
MN-60 NV32e|RlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHoeHR{UUN3ME2yMlI6QTJ|IN88US=> NXm1[YhoW0GQR1XS
OAW-28 MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXveVRKSzVyPUKuNlk6PTFizszN NWjmVXNpW0GQR1XS
NCI-H2228 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfrTWM2OD1{LkOxOVUzKM7:TR?= NU\ieG9pW0GQR1XS
ABC-1 MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJwM{OyOVMh|ryP M{LJWnNCVkeHUh?=
LS-513 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTJwM{O0PFQh|ryP NESxdZRUSU6JRWK=
KS-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL4TWM2OD1{LkO4NVkyKM7:TR?= MW\TRW5ITVJ?
NB69 M4XoWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPuSIdOUUN3ME2yMlM5QTh|IN88US=> MX\TRW5ITVJ?
VM-CUB-1 MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPXTWM2OD1{LkO5NFg{KM7:TR?= NXLs[Jo6W0GQR1XS
D-423MG M3nMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrpTWM2OD1{LkSxNFQ1KM7:TR?= MV3TRW5ITVJ?
EW-18 NFHXdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJwNEG5N|kh|ryP NF;kd|RUSU6JRWK=
YH-13 MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJwNE[xOVMh|ryP NXX6PWJvW0GQR1XS
T-24 M4L6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13MV2lEPTB;Mj60O|g5OSEQvF2= MoTKV2FPT0WU
ES8 NFvDUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTJwNEmyPFch|ryP M4SzSHNCVkeHUh?=
ES3 NHT0dohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJwNEm3OVkh|ryP MlLCV2FPT0WU
RXF393 NFLa[WJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;6[GRKSzVyPUKuOlA1QDdizszN NHPmTHBUSU6JRWK=
RPMI-8226 NFLv[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfmOW5KSzVyPUKuOlI6PTNizszN NYLnUIhiW0GQR1XS
AGS NGTSU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYC3[YRoUUN3ME2yMlczOTN5IN88US=> NWrvZohiW0GQR1XS
HCC1395 M2TGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7BeYg4UUN3ME2yMlc2OTh5IN88US=> M3rlSHNCVkeHUh?=
MV-4-11 NGmxZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfyb3FiUUN3ME2yMlc2OjZ4IN88US=> MWXTRW5ITVJ?
A204 MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlexTWM2OD1{LkizPFczKM7:TR?= MmPsV2FPT0WU
MCF7 MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJwOE[xNVch|ryP Mn;XV2FPT0WU
SNU-423 NXHoTYpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\kTWM2OD1{Lki5NlQzKM7:TR?= M3TiV3NCVkeHUh?=
NCI-H1048 NUfJV3pOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTJwOU[4OlUh|ryP MnviV2FPT0WU
GR-ST NVnYe3VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj0fZZqUUN3ME2zMlA1PjFzIN88US=> M3TWbHNCVkeHUh?=
EoL-1- NVP0NnJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HIeWlEPTB;Mz6wO|A2QCEQvF2= MUPTRW5ITVJ?
HuH-7 MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\QNGlEPTB;Mz6wPVQ3PCEQvF2= MUjTRW5ITVJ?
OS-RC-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTNwMUGxPUDPxE1? Ml[4V2FPT0WU
EW-3 NHvR[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rSbGlEPTB;Mz6xPVUzQSEQvF2= MmD0V2FPT0WU
NCI-H747 M{TWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPz[FNLUUN3ME2zMlIxPjl2IN88US=> M4XVV3NCVkeHUh?=
EW-16 M1K1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGq2blVKSzVyPUOuNlE5PzlizszN MVzTRW5ITVJ?
DOK MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVu4[|BOUUN3ME2zMlIzQDV7IN88US=> MWLTRW5ITVJ?
HCC2157 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1faUWlEPTB;Mz6zPFE4QSEQvF2= NYT2NHpjW0GQR1XS
OVCAR-3 Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXUVGtKSzVyPUOuOFA4QDZizszN M3L3UHNCVkeHUh?=
NCI-H1623 M12wcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTNwNEGyNlQh|ryP NFmxXGFUSU6JRWK=
H4 NVzId2RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPVTWM2OD1|LkS1OlI3KM7:TR?= M3jYbHNCVkeHUh?=
SW1710 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLBWIZyUUN3ME2zMlQ3Pjd6IN88US=> NXjNXo5{W0GQR1XS
RT-112 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnywTWM2OD1|LkWyN|g5KM7:TR?= MVzTRW5ITVJ?
DMS-114 NWXzeItZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi1XWtCUUN3ME2zMlYzOjd6IN88US=> M{X3SnNCVkeHUh?=
AN3-CA M3rIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTNwNkK0OVYh|ryP NFPZW3NUSU6JRWK=
KNS-62 NWH4[|VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTUTWM2OD1|Lk[zN|M5KM7:TR?= NYDhVo5IW0GQR1XS
SJRH30 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmSzTWM2OD1|Lk[5NVIzKM7:TR?= M1:4d3NCVkeHUh?=
G-402 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PvfWlEPTB;Mz63NFcyOSEQvF2= NFLpVnNUSU6JRWK=
MHH-PREB-1 NIrhVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf1dmFKSzVyPUOuO|IxOzhizszN NXLtTYdTW0GQR1XS
P30-OHK MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHON49MUUN3ME2zMlgxQTd4IN88US=> MVjTRW5ITVJ?
RVH-421 NFvXWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXqTWM2OD1|LkixO|g5KM7:TR?= M3r5bHNCVkeHUh?=
LU-134-A M{\6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\OTWM2OD1|Lki4OFI5KM7:TR?= MUfTRW5ITVJ?
ECC10 NFfHc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTNwOUO2NlIh|ryP NIfXOnNUSU6JRWK=
TGW MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PRfGlEPTB;ND6wNlMxPSEQvF2= MVfTRW5ITVJ?
MLMA NYL0V2FOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[wd2lEPTB;ND6wNlk3PiEQvF2= NI\qWm1USU6JRWK=
SCC-25 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nJbWlEPTB;ND6wOlU3PiEQvF2= MYnTRW5ITVJ?
TYK-nu MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vXUWlEPTB;ND6wPVU{PCEQvF2= NUfHeldFW0GQR1XS
LAMA-84 NF\PXmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M132bWlEPTB;ND6xOFE6OSEQvF2= NUL2e4xNW0GQR1XS
Calu-3 NYjYNohVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv0TYN6UUN3ME20MlI1PDF4IN88US=> M{LRe3NCVkeHUh?=
NCI-H460 M{[ycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zyTGlEPTB;ND6yOlQ1OyEQvF2= MYLTRW5ITVJ?
EGI-1 MkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDKTWM2OD12LkO3O|c5KM7:TR?= MnK0V2FPT0WU
NCI-H292 MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS1TWM2OD12LkO4NVQ3KM7:TR?= NGjIdW1USU6JRWK=
HCE-T MlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XhZ2lEPTB;ND60NVU4QSEQvF2= NHXqcoRUSU6JRWK=
EW-11 M3PnUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTRwNEG4N|gh|ryP MUTTRW5ITVJ?
ATN-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTRwNESzNFQh|ryP NF;xVWVUSU6JRWK=
NB5 NIHoW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTRwNUO2PVch|ryP MonnV2FPT0WU
KLE M{HLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTRwN{CxPVgh|ryP NIfMWoRUSU6JRWK=
CAL-39 MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTRwN{KxOFYh|ryP MVTTRW5ITVJ?
TI-73 NFXvbIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\HTnFoUUN3ME20MlgxPjB7IN88US=> NWrWXnd3W0GQR1XS
HO-1-N-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4faU2lEPTB;ND65OFIh|ryP M1y1UXNCVkeHUh?=
786-0 MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\BTWM2OD12Lkm0Olc{KM7:TR?= NF;Q[o5USU6JRWK=
SK-N-DZ NFq1cI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\iTWM2OD12Lkm2NVQzKM7:TR?= MVPTRW5ITVJ?
NCI-H446 Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTVwMkCwNFkh|ryP NF33d2pUSU6JRWK=
ETK-1 NVPTTVZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVSwbW82UUN3ME21MlIyOTZ3IN88US=> MmezV2FPT0WU
BT-20 M3KydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe4Z4FKSzVyPUWuNlE{PTNizszN MoHxV2FPT0WU
MEL-HO MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TEc2lEPTB;NT6zO|M{PiEQvF2= M1n5ZnNCVkeHUh?=
CAL-27 NH3rbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTVwNE[zN|kh|ryP MYrTRW5ITVJ?
SW872 MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHP5b21KSzVyPUWuOVk1OjhizszN NWXvZphGW0GQR1XS
RPMI-2650 NFOyTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTVwNk[xPVkh|ryP MkXTV2FPT0WU
PFSK-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDxTWM2OD13LkeyO|MzKM7:TR?= Mln5V2FPT0WU
SF295 M{jlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\qUplNUUN3ME21MlgxPjN|IN88US=> Mn3iV2FPT0WU
Becker NVziZlBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXNTWM2OD13Lki2OFczKM7:TR?= M2D2OnNCVkeHUh?=
Saos-2 NHzxTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTiUYlKSzVyPUWuPFY2OyEQvF2= NWTkTHh1W0GQR1XS
SK-OV-3 MlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTVwOUm4NVYh|ryP NWPESYlvW0GQR1XS
VMRC-RCZ MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\nTWM2OD14LkC4O|c{KM7:TR?= M{[w[3NCVkeHUh?=
EW-22 NFi4[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r3SmlEPTB;Nj6xPVY1QSEQvF2= NUfudFFHW0GQR1XS
BT-474 NGLGVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXyOZNHUUN3ME22MlI{OyEQvF2= NVXmVVJFW0GQR1XS
BFTC-909 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS3UWFyUUN3ME22MlMxOzR3IN88US=> MmHrV2FPT0WU
NB12 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnyXJNKSzVyPU[uN|kxPzFizszN MmHmV2FPT0WU
D-263MG NVLvfVVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M364emlEPTB;Nj60OVE3QSEQvF2= NYDLVnRpW0GQR1XS
SNB75 NEXhO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7OfoVrUUN3ME22MlYxOTR|IN88US=> MW\TRW5ITVJ?
A704 NWr4OJhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;o[WFQUUN3ME22MlY{ODZizszN NGi3[GxUSU6JRWK=
NCI-H1693 MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjyUmFKSzVyPU[uOlM3ODRizszN NEPO[plUSU6JRWK=
LN-405 NFnRbYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTZwN{m2O|Ih|ryP NXjySI5oW0GQR1XS
CHL-1 NEDTNnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NECz[IdKSzVyPU[uPFAxPzlizszN MXzTRW5ITVJ?
A498 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfYNGpwUUN3ME22MlgyQTZzIN88US=> M17sUHNCVkeHUh?=
TE-12 NIL0SmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L5V2lEPTB;Nj64N|gyPyEQvF2= MXrTRW5ITVJ?
TE-6 M3\iZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXT[41KSzVyPU[uPVMxOzhizszN NVeyUWl7W0GQR1XS
AU565 M3HFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DIV2lEPTB;Nj65Olk2PyEQvF2= M{fkdXNCVkeHUh?=
RD M3Lvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTZwOUiyPFQh|ryP MY\TRW5ITVJ?
SW1463 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPUTWM2OD15LkGxNVY5KM7:TR?= NEGxdZhUSU6JRWK=
LU-99A MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\yd2lEPTB;Nz6xOFMzOiEQvF2= Mln1V2FPT0WU
NCI-H28 MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTdwMkmyOEDPxE1? MYfTRW5ITVJ?
MC-IXC NHvjeYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4OzZmlEPTB;Nz60PFU4PiEQvF2= NUfZXHFXW0GQR1XS
GP5d MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnqTWM2OD15LkS4O|Y1KM7:TR?= Mn\4V2FPT0WU
GB-1 NHrGelFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLaTWM2OD15LkW0PFA1KM7:TR?= M1:4OXNCVkeHUh?=
CAL-33 MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTdwNk[yN|Mh|ryP MmLHV2FPT0WU
MSTO-211H M{PVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DxVGlEPTB;Nz62O|M{PiEQvF2= Mnz0V2FPT0WU
TE-5 NY\tR5YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTdwN{mzN|Qh|ryP MVPTRW5ITVJ?
D-566MG NYH3b41UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHUTlVSUUN3ME24MlA1PDJ7IN88US=> M1HrNXNCVkeHUh?=
JVM-3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli0TWM2OD16LkG1NlY5KM7:TR?= MYrTRW5ITVJ?
T98G MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRThwMUiwOlch|ryP NF;Y[GNUSU6JRWK=
HCC1954 M{PMRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHmTWM2OD16LkS1NVA1KM7:TR?= NFG0ZXZUSU6JRWK=
SF126 NVvyfFF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRThwNEW5N|Yh|ryP MYfTRW5ITVJ?
LB996-RCC NX[5fIZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnBenFNUUN3ME24MlU{OjV5IN88US=> NUDTbmhPW0GQR1XS
SKG-IIIa NUHVSHpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;JSm9MUUN3ME24MlY{ODZ7IN88US=> NXzObIFkW0GQR1XS
NCI-SNU-1 M1T4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXhWXU4UUN3ME24MlY1PjR|IN88US=> M2XmOnNCVkeHUh?=
LB771-HNC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PDfWlEPTB;OD62OFY6PiEQvF2= MVLTRW5ITVJ?
SCC-4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jhNGlEPTB;OD62PFIyQSEQvF2= NUfX[YVwW0GQR1XS
CAMA-1 NYj3SoZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLQ[oFKSzVyPUiuO|cyPDZizszN MoG2V2FPT0WU
D-502MG MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrTdJNjUUN3ME24Mlc5PjJ7IN88US=> M3PNVnNCVkeHUh?=
ESS-1 MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRThwOEi3NFQh|ryP MnPrV2FPT0WU
HEC-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vBWmlEPTB;OD64PVg3PiEQvF2= NUTaOpVsW0GQR1XS
NB10 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG4dG1HUUN3ME25MlAzOjJ2IN88US=> NVHBcJdRW0GQR1XS
8505C MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rXS2lEPTB;OT6wOFI{OiEQvF2= MlPsV2FPT0WU
EFO-27 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmGwTWM2OD17LkG2OFEzKM7:TR?= Mnj6V2FPT0WU
HN NWLFTXhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrOPFhKUUN3ME25MlE3PjJ6IN88US=> NFvvW2tUSU6JRWK=
DSH1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TZXGlEPTB;OT6yNFg4KM7:TR?= NI\DTHNUSU6JRWK=
NBsusSR M4nsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XvcGlEPTB;OT6yO|QxOiEQvF2= MkG3V2FPT0WU
LS-123 NXi4[pNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD0TWM2OD17LkOxO|YyKM7:TR?= NXzwWo9oW0GQR1XS
SHP-77 NX7WNWd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfvT444UUN3ME25MlM6QTN3IN88US=> M2Tad3NCVkeHUh?=
ACN MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvUVJJZUUN3ME25MlU{Ojd5IN88US=> MU\TRW5ITVJ?
U251 MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTlwNkW1OFQh|ryP NUj5[FhDW0GQR1XS
A431 MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S3VGlEPTB;OT64NFI{QCEQvF2= NX3QbVBTW0GQR1XS
5637 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTlwOES5PFQh|ryP NXXSTWg2W0GQR1XS
MDA-MB-157 M2f5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:0TWM2OD17LkmyPFc5KM7:TR?= M4XKZ3NCVkeHUh?=
A101D MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fYT2lEPTB;OT65PVk4PCEQvF2= M{iyVnNCVkeHUh?=
YKG-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nrfWlEPTB;MUCuNlAxPiEQvF2= MXjTRW5ITVJ?
LAN-6 NH30OXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTFyLkKxOlQh|ryP MoHNV2FPT0WU
OVCAR-5 Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTJTWM2OD1zMD6yOFM{KM7:TR?= MX;TRW5ITVJ?
A549 NVzjbI1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\6Z2RKSzVyPUGwMlM6PzNizszN M{frXHNCVkeHUh?=
no-11 NUDFNHJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP2[WFKSzVyPUGwMlQ{PTNizszN MmPhV2FPT0WU
SF539 M3HReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Tae2lEPTB;MUCuPVA1OSEQvF2= NXHPeHZUW0GQR1XS
A388 M3jYdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFzLkO4PVch|ryP NVHCeHRJW0GQR1XS
DEL NXLhW3hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:0XGlEPTB;MUGuOFI1KM7:TR?= M4DyNXNCVkeHUh?=
SW954 Mn[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIeyT5FKSzVyPUGxMlQ3PjhizszN MWLTRW5ITVJ?
TK10 NHzYT|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzaPFVKSzVyPUGxMlUzPzFizszN MkjwV2FPT0WU
SW756 NG\SSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTFzLkWyPVQh|ryP M2TDTHNCVkeHUh?=
PC-3 NXexcVNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml61TWM2OD1zMT61O|Y1KM7:TR?= NWXXd3FSW0GQR1XS
ONS-76 NF3aU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjMfYdZUUN3ME2xNU43OzZizszN MV;TRW5ITVJ?
A427 NWfuOXIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTFzLkewPVMh|ryP MoPSV2FPT0WU
MEG-01 NFTIcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[5U2lEPTB;MUGuO|UxQSEQvF2= MljqV2FPT0WU
BB30-HNC NFjIZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTJTWM2OD1zMT63PVgzKM7:TR?= M1m5dXNCVkeHUh?=
NCI-H1299 M{fze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX0TWM2OD1zMT64NFk{KM7:TR?= NU\rNHBJW0GQR1XS
GCT NHns[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFzLkiyNlgh|ryP NXfpVXViW0GQR1XS
D-247MG M4\oT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v4[GlEPTB;MUGuPVY3OyEQvF2= MVrTRW5ITVJ?
CFPAC-1 NVTRV2ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFzLkm3PFIh|ryP MkHLV2FPT0WU
EKVX MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTpb3A2UUN3ME2xNk4xOzF|IN88US=> NVfCVJNVW0GQR1XS
CAL-51 M3iyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nO[GlEPTB;MUKuNFcyPiEQvF2= MnP3V2FPT0WU
BB49-HNC Ml;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnBU4FjUUN3ME2xNk4yOTd5IN88US=> MYjTRW5ITVJ?
RPMI-7951 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTF{LkG4OVQh|ryP MXTTRW5ITVJ?
RH-1 MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3G2ZmlEPTB;MUKuNlE5PCEQvF2= MX7TRW5ITVJ?
BCPAP NYnkPY5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnpOoxKSzVyPUGyMlQ4PDlizszN NVuzZotCW0GQR1XS
GCIY NWSyNodTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXQTWM2OD1zMj61NlA6KM7:TR?= M2LkZXNCVkeHUh?=
KNS-81-FD M2L3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7FTWM2OD1zMj61PFY6KM7:TR?= MV;TRW5ITVJ?
KYSE-140 NIHpV|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPzOnVKSzVyPUGyMlg2QTVizszN Mn7lV2FPT0WU
Ca-Ski NFjpTWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTmTWM2OD1zMj65NFQyKM7:TR?= MVzTRW5ITVJ?
TGBC1TKB NV[yS4s5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDEcVR3UUN3ME2xNk46OTF3IN88US=> M4TONHNCVkeHUh?=
HCC1187 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLNTWM2OD1zMz6xPVEzKM7:TR?= NUjCVXN1W0GQR1XS
SJSA-1 NYXvco9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W4R2lEPTB;MUOuNlMzPyEQvF2= NVfxNXZYW0GQR1XS
CTV-1 MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvLUY1nUUN3ME2xN{4{PDVizszN NH61R2JUSU6JRWK=
WM-115 M{j3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HhZWlEPTB;MUOuOlQ5OyEQvF2= Mn7qV2FPT0WU
CHP-212 MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF|Lkm3N|kh|ryP NXHyb2t4W0GQR1XS
SCC-15 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\peGlEPTB;MUOuPVc4PSEQvF2= M1rke3NCVkeHUh?=
BPH-1 NUH4WHNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHiSZFKSzVyPUG0MlE3PjRizszN NXTPd5hoW0GQR1XS
SW780 M1y1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHvPXNjUUN3ME2xOE42ODJ3IN88US=> NV;Hcot4W0GQR1XS
NCI-H2291 M1W3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLRTWM2OD1zND61PFc5KM7:TR?= NEPFWW9USU6JRWK=
JEG-3 NWDpdmpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF2Lk[zNlYh|ryP MVjTRW5ITVJ?
CAL-120 NFiyRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPSTWFnUUN3ME2xOE44ODJ5IN88US=> M2[weXNCVkeHUh?=
NCI-H23 M4\Kbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnzNnk4UUN3ME2xOE44QTl5IN88US=> MkfHV2FPT0WU
MS-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTF2Lkm2NVEh|ryP NYjBTY5jW0GQR1XS
PC-14 NEDjN4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S2[GlEPTB;MUSuPVY2PCEQvF2= MWHTRW5ITVJ?
D-283MED NXzjcI57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTF3LkCxNVEh|ryP NHvoPGtUSU6JRWK=
OE19 M{fLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDqN3JKSzVyPUG1MlE2PDFizszN M2GxXXNCVkeHUh?=
CAS-1 NYf0XldET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3vWld1UUN3ME2xOU41OTh2IN88US=> MWHTRW5ITVJ?
NCI-H727 NEPlNWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\Qe2lEPTB;MUWuOFIzOSEQvF2= MX3TRW5ITVJ?
SiHa MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LCcWlEPTB;MUWuO|U6PCEQvF2= NVu4OHVyW0GQR1XS
BFTC-905 NIfN[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXe4dYZVUUN3ME2xOU44Pjl2IN88US=> MYjTRW5ITVJ?
MDA-MB-453 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXXTWM2OD1zNj6xOlQzKM7:TR?= NW\SfXpQW0GQR1XS
HuP-T3 M2Pib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDKe3BKSzVyPUG2MlY{PzNizszN NETybFRUSU6JRWK=
SK-LU-1 NUfXUVVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF4Lk[5OVYh|ryP M1LmbHNCVkeHUh?=
Detroit562 M3Pkfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTqVok5UUN3ME2xOk44OzF6IN88US=> MnPaV2FPT0WU
HCC1569 M2fyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\GdY9KSzVyPUG2Mlg{OzdizszN NUPLboFSW0GQR1XS
SK-MES-1 NWO0c5QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fjTGlEPTB;MU[uPFQyQSEQvF2= M136XnNCVkeHUh?=
BB65-RCC M161Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz2TWM2OD1zNz6wOFc6KM7:TR?= Mlu1V2FPT0WU
LOXIMVI Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDXTWM2OD1zNz6wO|A4KM7:TR?= NGS1dI5USU6JRWK=
SW1783 MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF5LkGyPEDPxE1? MWfTRW5ITVJ?
NH-12 NVHCTHlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYL6bZdoUUN3ME2xO{4{OzB|IN88US=> NVzv[3I3W0GQR1XS
UACC-257 M2\rdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13Ce2lEPTB;MUeuOVUyOiEQvF2= MXPTRW5ITVJ?
KOSC-2 NWH3[G8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF5Lk[3OVch|ryP MWLTRW5ITVJ?
KG-1 M1zQZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFW5UJlKSzVyPUG3MlY6OzdizszN NYrYZnRKW0GQR1XS
M059J NXrMNnk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;6UYNKSzVyPUG3MlcxOyEQvF2= NEfPUmZUSU6JRWK=
MHH-NB-11 M3Gw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\yTWM2OD1zNz65Olc{KM7:TR?= NHjKc4NUSU6JRWK=
EW-1 NUj4[lJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjUNWJKSzVyPUG4MlE{QDJizszN MYDTRW5ITVJ?
CAL-85-1 NEfXcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rNNWlEPTB;MUiuNlM2PyEQvF2= Mn\XV2FPT0WU
639-V MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYe5clB[UUN3ME2xPE4{OzV2IN88US=> NVjm[283W0GQR1XS
C32 MkPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTF6LkS3Nlch|ryP MojUV2FPT0WU
KM-H2 MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHS3XHZKSzVyPUG4MlUzOzJizszN MnjSV2FPT0WU
A253 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTBTWM2OD1zOD63Nlg3KM7:TR?= M36wWXNCVkeHUh?=
NCI-N87 MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF6LkmwNFgh|ryP MVjTRW5ITVJ?
8-MG-BA NVnESmV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzpTWM2OD1zOT6wOlQ3KM7:TR?= NWHBWJQyW0GQR1XS
GI-ME-N MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLkR|FtUUN3ME2xPU4yPTR4IN88US=> MUTTRW5ITVJ?
8305C MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF7LkKyPFYh|ryP MX7TRW5ITVJ?
TE-8 M4jhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXnTWM2OD1zOT6zNFI1KM7:TR?= MlLLV2FPT0WU
KYSE-270 NIDZOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJyLkCyNVch|ryP M1H5dXNCVkeHUh?=
HL-60 Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn1TJRKSzVyPUKwMlA6PDFizszN NVjlRZU3W0GQR1XS
Mo-T NWjuUpFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzwTWM2OD1{MD6xOlY2KM7:TR?= MlL5V2FPT0WU
NCI-H1355 MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;jfWlEPTB;MkCuN|M4PCEQvF2= NETM[3pUSU6JRWK=
HT-1080 M{nJT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\DTWM2OD1{MD61OFk4KM7:TR?= MUTTRW5ITVJ?
MIA-PaCa-2 Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Wyb2lEPTB;MkCuOlg5OyEQvF2= M3XvdXNCVkeHUh?=
NCI-H441 NEf6OYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYiycGFxUUN3ME2yNE44Ozd7IN88US=> MlGyV2FPT0WU
LCLC-97TM1 MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfSe2t[UUN3ME2yNE45OTN2IN88US=> M{TrcHNCVkeHUh?=
HT-3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoroTWM2OD1{MT61OlMyKM7:TR?= MX;TRW5ITVJ?
22RV1 NVnkNFhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJzLkW2PFUh|ryP M{L1bnNCVkeHUh?=
LK-2 NGe2S2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGj0UFlKSzVyPUKxMlU6PTNizszN NFjTZpZUSU6JRWK=
CW-2 NX35fZJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJzLk[wOlkh|ryP NWi3ZotpW0GQR1XS
KYSE-510 NIT2WXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTJzLk[wPVUh|ryP M2PmSnNCVkeHUh?=
CGTH-W-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJzLkexOlYh|ryP M3rCcHNCVkeHUh?=
NCI-H661 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XOfGlEPTB;MkKuNFM1KM7:TR?= MmfzV2FPT0WU
KU-19-19 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jRb2lEPTB;MkKuNVY6PyEQvF2= NHW3cWxUSU6JRWK=
NCI-H2122 M3nhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJ{LkK0N|Ih|ryP NGPkV2NUSU6JRWK=
NCI-H526 Mlf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWW1OppiUUN3ME2yNk4{QDl3IN88US=> MXzTRW5ITVJ?
NCI-H1650 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjWTWM2OD1{Mj63OlQh|ryP MknwV2FPT0WU
AM-38 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13CSGlEPTB;MkKuPFY5QSEQvF2= MmniV2FPT0WU
NCI-H2405 MkL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPMTWM2OD1{Mz6yOVM{KM7:TR?= NFXWN5ZUSU6JRWK=
M14 MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj5V4RKSzVyPUKzMlQxQDhizszN NHX5SnFUSU6JRWK=
ES4 NH3HcpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3BbHBKSzVyPUKzMlQzOzJizszN MXvTRW5ITVJ?
DJM-1 NUXsdG9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHQfGw3UUN3ME2yN{42OjN2IN88US=> M{Dwc3NCVkeHUh?=
S-117 MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jEOWlEPTB;MkOuO|Y2OSEQvF2= NIH3[IVUSU6JRWK=
MZ2-MEL MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJ|Lke3OVkh|ryP M1vZS3NCVkeHUh?=
SK-MEL-2 NUW5UJRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4qwb2lEPTB;MkOuPFE{OyEQvF2= M1HzR3NCVkeHUh?=
HCC1806 M{PGN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XYXmlEPTB;MkOuPFcxQSEQvF2= NGHvbYpUSU6JRWK=
NMC-G1 M3rTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTJ2LkKyNlYh|ryP MkPWV2FPT0WU
DK-MG MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnnTWM2OD1{ND6yPVQh|ryP NWj2UG1iW0GQR1XS
SK-N-FI NWTrW5FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XwTGlEPTB;MkSuN|MxOiEQvF2= NILpcpVUSU6JRWK=
KINGS-1 NEPBToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfxT|BqUUN3ME2yOE41QDd2IN88US=> Mn3IV2FPT0WU
HCC2998 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M334cmlEPTB;MkSuOFg5PSEQvF2= Ml[5V2FPT0WU
ALL-PO NFjBNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJ2Lk[xPUDPxE1? MYrTRW5ITVJ?
MPP-89 M1vrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJ3LkC0OVgh|ryP NEXzU5hUSU6JRWK=
NCI-H2342 Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XkTWlEPTB;MkWuNVk2OyEQvF2= M2e5THNCVkeHUh?=
TE-1 NUTWcnQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7wN|lKSzVyPUK1MlM2PjNizszN M4T4eHNCVkeHUh?=
RH-18 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJ3LkW5NVgh|ryP NW\BfodbW0GQR1XS
HT-1376 NWrSRpVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n4WWlEPTB;MkWuOlQ3PSEQvF2= MUjTRW5ITVJ?
U-2-OS MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz2TWFKSzVyPUK1MlY5QDhizszN M3Tse3NCVkeHUh?=
BT-549 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3KfoVKSzVyPUK1MlkxOTFizszN MXjTRW5ITVJ?
NCI-H1755 NV3jNnZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TjemlEPTB;MkWuPVk1PSEQvF2= MXTTRW5ITVJ?
EW-13 NIC1cJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fMUGlEPTB;Mk[uNFI4PCEQvF2= NFH1PGNUSU6JRWK=
NB13 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn3XFlKSzVyPUK2MlA6PDlizszN M{f0O3NCVkeHUh?=
NUGC-3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;lTWM2OD1{Nj6yNVA{KM7:TR?= NGLLW2VUSU6JRWK=
GMS-10 NXHh[FQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXPTWM2OD1{Nj6yN|U{KM7:TR?= NWD0WI1qW0GQR1XS
CHP-134 NGDReZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDjXGM1UUN3ME2yOk4{QDZ5IN88US=> M13QT3NCVkeHUh?=
SW962 NIjV[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJ4LkWwNlEh|ryP NIn3b4tUSU6JRWK=
SNU-449 NWGyNXg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\ETWM2OD1{Nz6wPFA{KM7:TR?= NEjkO2NUSU6JRWK=
HuP-T4 NH;WbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LydmlEPTB;MkeuNFg4QSEQvF2= NILXRnFUSU6JRWK=
SW948 MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\aXWlEPTB;MkeuNVM1PCEQvF2= NFXHWYVUSU6JRWK=
NCI-H226 MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlKwTWM2OD1{Nz60OVc5KM7:TR?= MY\TRW5ITVJ?
SK-PN-DW NX;zUWJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LERWlEPTB;MkeuOlAyOiEQvF2= MY\TRW5ITVJ?
GI-1 MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2e1e2lEPTB;MkeuO|IyKM7:TR?= M3fPc3NCVkeHUh?=
CAL-12T MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLve|FtUUN3ME2yPE4yOTF{IN88US=> NYjlPVFQW0GQR1XS
YAPC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXqTWM2OD1{OD6yOVY1KM7:TR?= NFTTN4ZUSU6JRWK=
SNU-C2B NWTNc41bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;YWnBKSzVyPUK4MlI6PjRizszN NV;SW2cxW0GQR1XS
RCC10RGB MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlGwTWM2OD1{OD61OFE4KM7:TR?= NXjmb5dYW0GQR1XS
ES7 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPhTWM2OD1{OT6xOFY2KM7:TR?= MYrTRW5ITVJ?
PANC-03-27 NGHLNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;WZoFKSzVyPUK5MlQ1PCEQvF2= NHX6b4pUSU6JRWK=
ES6 NFjSNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYH3SVY1UUN3ME2yPU45OTV5IN88US=> MkXPV2FPT0WU
HT-1197 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUC1OHlOUUN3ME2zNE4xPTl6IN88US=> Ml3DV2FPT0WU
ZR-75-30 M1rZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7MPVVKSzVyPUOwMlI{QDNizszN NV:wN253W0GQR1XS
DB M{H3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfzd|BKSzVyPUOwMlQ6PDJizszN NWfxOXBCW0GQR1XS
OCI-AML2 M{XWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXju[GJDUUN3ME2zNU4xPjlizszN M2T6OHNCVkeHUh?=
NCI-H2170 Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTNzLki1NVYh|ryP NIfkN5lUSU6JRWK=
IST-MES1 NGX1UnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnINnZKSzVyPUOyMlI5QTdizszN MYjTRW5ITVJ?
769-P MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrjWVFKSzVyPUOyMlM3PDFizszN MofvV2FPT0WU
COR-L23 M{L1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LONWlEPTB;M{KuPVA4OyEQvF2= M3:zSXNCVkeHUh?=
SW626 M{HhNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nQW2lEPTB;M{OuNVc4PiEQvF2= NUPSPVJKW0GQR1XS
LU-139 NWXV[JgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK3TWM2OD1|Mz62OlA2KM7:TR?= MoHDV2FPT0WU
HT-144 MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXOyNZBFUUN3ME2zN{45PjNizszN MYjTRW5ITVJ?
CaR-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfWNplKSzVyPUOzMlk5OjJizszN M37nWnNCVkeHUh?=
OE33 NIPSOZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLiTWM2OD1|ND6yPFU2KM7:TR?= M{nMR3NCVkeHUh?=
COLO-800 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLieHhKSzVyPUO0MlM3PDdizszN NHz3R41USU6JRWK=
NB14 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nXU2lEPTB;M{SuOFY5PCEQvF2= M1r1UHNCVkeHUh?=
KURAMOCHI MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTN4LkGxPVgh|ryP NGjhb5VUSU6JRWK=
SW48 NED6ZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\wTWM2OD1|Nj6yOFc1KM7:TR?= NUnSNXROW0GQR1XS
Daoy MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHCUFNKSzVyPUO2MlY2OzhizszN M1XvTHNCVkeHUh?=
TGBC24TKB MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPCTWM2OD1|Nj62O{DPxE1? MoPHV2FPT0WU
DU-4475 NX35VW9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPWWpVKSzVyPUO2MlkxOzNizszN MYPTRW5ITVJ?
SW1417 NFqxU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfGbJVKSzVyPUO4MlA2PTJizszN Mkn5V2FPT0WU
EFO-21 NEC0T25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlv6TWM2OD1|OD65N|Q6KM7:TR?= MVHTRW5ITVJ?
MG-63 NYLSOIp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i4XWlEPTB;M{muN|QzPCEQvF2= NXW3dGJyW0GQR1XS
LC-2-ad M2GzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFy4XIlKSzVyPUO5MlU2OTJizszN M135VHNCVkeHUh?=
NOMO-1 MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTOUXltUUN3ME2zPU45Ojd2IN88US=> Mlf3V2FPT0WU
COLO-741 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HwTGlEPTB;NECuNVMxPCEQvF2= Mk[4V2FPT0WU
BxPC-3 MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG1PY1KSzVyPUSwMlU3QDZizszN MWLTRW5ITVJ?
HSC-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\iTWM2OD12MD65NVE{KM7:TR?= MoSxV2FPT0WU
UMC-11 NGnPVW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrVfIR2UUN3ME20NU4zPjNizszN NVSySJNNW0GQR1XS
HCC1937 Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES5TIFKSzVyPUSyMlc5PDNizszN NHG0VmVUSU6JRWK=
Calu-6 NVfJb3Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGq5fGpKSzVyPUSzMlI{QDJizszN NEDP[WNUSU6JRWK=
NCI-H1573 M2jRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTR|LkO0O|ch|ryP NE\mTHpUSU6JRWK=
SK-N-AS MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkC2TWM2OD12Mz62NFE6KM7:TR?= MWTTRW5ITVJ?
PSN1 NWDCSpB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfQTWM2OD12NT6yOVQ5KM7:TR?= NWS2PGNIW0GQR1XS
TE-11 MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LlXGlEPTB;NEWuOFg1OiEQvF2= NILUVHZUSU6JRWK=
NCI-H1155 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTR3Lki5Olch|ryP MUDTRW5ITVJ?
KM12 NXjaeW5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkThTWM2OD12NT65NFc3KM7:TR?= MlLmV2FPT0WU
RO82-W-1 NH23TWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjrTWM2OD12Nj65PFIzKM7:TR?= MlHlV2FPT0WU
SW1573 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHGTVBqUUN3ME20O{4{PzN4IN88US=> MmL3V2FPT0WU
CAKI-1 NXK4cY5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzJTWM2OD12OD6yPFQ2KM7:TR?= NH;KcFNUSU6JRWK=
U-118-MG MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDZTWM2OD12OD6zO|AzKM7:TR?= MontV2FPT0WU
KYSE-520 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3ZeHpmUUN3ME20PE41ODF4IN88US=> MVHTRW5ITVJ?
HT55 NVjQe2FOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYO2WHpmUUN3ME20PU4yPDd2IN88US=> MoD5V2FPT0WU
ChaGo-K-1 M{TNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYCzSotMUUN3ME20PU41Pzl|IN88US=> NGm4RYZUSU6JRWK=
IA-LM MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfGTXBKSzVyPUW0MlY{OjJizszN MlTBV2FPT0WU
UACC-62 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHTd5R1UUN3ME21OU4yODR4IN88US=> NYPCcVZiW0GQR1XS
MKN7 M1:2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjIeGl5UUN3ME21Ok4xOjh3IN88US=> Mn7iV2FPT0WU
HPAF-II MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mny4TWM2OD13Nj60NFc{KM7:TR?= Mk\kV2FPT0WU
NTERA-S-cl-D1 Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHsb|FKSzVyPUW3Mlc4QCEQvF2= MYXTRW5ITVJ?
FTC-133 NUXsNXdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTV6LkC5Olkh|ryP M1HvfHNCVkeHUh?=
MHH-ES-1 NIPGWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvFdlhRUUN3ME21PE41QDF2IN88US=> M1Lxc3NCVkeHUh?=
JVM-2 M4r1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTV6Lkm1NFYh|ryP M4fUU3NCVkeHUh?=
TCCSUP NED2OXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnFNYdKSzVyPUW5MlUzPzlizszN MXrTRW5ITVJ?
COLO-824 MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPlbHpxUUN3ME22NE4xPzF7IN88US=> MUTTRW5ITVJ?
647-V Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIW0eXhKSzVyPU[wMlE{PDdizszN M1HafHNCVkeHUh?=
HD-MY-Z M{PRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTsTWM2OD14MD61Nlk1KM7:TR?= MVLTRW5ITVJ?
LS-411N MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHq4[YdKSzVyPU[xMlM6ODNizszN NULY[oRZW0GQR1XS
NCI-H596 M3XaSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTZ{Lke0PVYh|ryP M{D5NHNCVkeHUh?=
C-33-A NV;LR2h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmq3TWM2OD14ND6wPVU4KM7:TR?= MYnTRW5ITVJ?
BHY NVfvZm9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTETWM2OD14ND6xNlQ2KM7:TR?= MmXNV2FPT0WU
KGN NW\yUHR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTZ2LkW1NVQh|ryP MoraV2FPT0WU
NCI-H1092 NEXPXlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTZ3LkCwPVUh|ryP MmWxV2FPT0WU
MZ1-PC M4nKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrJZYd[UUN3ME22OU42PjR7IN88US=> NFXBV3ZUSU6JRWK=
LB831-BLC MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[5TWM2OD14NT64OFgyKM7:TR?= NWfCNWZQW0GQR1XS
SW620 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;5bWlEPTB;Nk[uNlA{QSEQvF2= NVfUS4x{W0GQR1XS
HuO-3N1 MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTZ6LkOyN|gh|ryP NHLa[lJUSU6JRWK=
SK-HEP-1 NXnGTIl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXlTWM2OD14OT65OFg3KM7:TR?= NWTzelRKW0GQR1XS
LCLC-103H MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV73PVVzUUN3ME23NE43PzB3IN88US=> MoPkV2FPT0WU
KYSE-70 NYXHOHh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTdyLke4N|Uh|ryP NW[2R2tuW0GQR1XS
Mewo MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvuZZFKSzVyPUexMlUxPSEQvF2= NY\qdmI4W0GQR1XS
COLO-668 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv1c3ltUUN3ME23NU45PDVzIN88US=> MWfTRW5ITVJ?
NCI-H522 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDyTWM2OD15Mj6zOFE{KM7:TR?= M4H0VHNCVkeHUh?=
NCI-H1437 NGD5dIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\aTWM2OD15ND60NFQ5KM7:TR?= NFnEOJZUSU6JRWK=
U-266 M3[2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3HUolpUUN3ME23OU41PTF4IN88US=> M1O1O3NCVkeHUh?=
MC116 M3;2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELwR4xKSzVyPUe1MlU4ODhizszN Mne4V2FPT0WU
PANC-10-05 NEjhNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDmZmhKSzVyPUe3MlQzPDNizszN NXHrVXhzW0GQR1XS
KYSE-180 NFPxRY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLsW5NKSzVyPUe3MlU1PTRizszN MlvBV2FPT0WU
JAR Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfzU2F[UUN3ME23PU4xPTR4IN88US=> MXfTRW5ITVJ?
CAL-62 NUfPSnBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXLXJZKSzVyPUiwMlA6PSEQvF2= NWXRfHdWW0GQR1XS
A3-KAW MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDlbFVDUUN3ME24NE4zOTV2IN88US=> NVXRN5hiW0GQR1XS
PANC-08-13 MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRThzLkG3Olgh|ryP NVjxO3ROW0GQR1XS
HSC-3 Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmX0TWM2OD16Mz6zNFcyKM7:TR?= MUPTRW5ITVJ?
HTC-C3 MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3YOW9MUUN3ME24N{41PzB{IN88US=> NX3TcWNHW0GQR1XS
KY821 NEfxU|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf0fZJVUUN3ME24OE4xQDl{IN88US=> NYXLU4FOW0GQR1XS
DoTc2-4510 NFzsdXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2SzXmlEPTB;OESuNlE5PSEQvF2= NILuTVFUSU6JRWK=
NCI-H1581 NV3PZmFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;Wb2lEPTB;OEWuOFY1OSEQvF2= MmT6V2FPT0WU
KARPAS-299 NYmzeXAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTh4LkG5O|ch|ryP MoP1V2FPT0WU
IST-MEL1 NGfiRmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrYT5NKSzVyPUi2Mlg5PzJizszN NYPWNlVQW0GQR1XS
KP-N-YS M2f2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrUbWRKSzVyPUi5MlkxOjhizszN MkXiV2FPT0WU
KYSE-410 M33Ve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTSPZhlUUN3ME25NU41ODR{IN88US=> NEXV[VdUSU6JRWK=
TE-10 NF;vepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTlzLkW2NVEh|ryP MXXTRW5ITVJ?
SK-MEL-1 NGLRSHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rNUWlEPTB;OUKuPVExPiEQvF2= MmPwV2FPT0WU
COLO-792 MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCxZ3ZtUUN3ME25OU4zPTZ2IN88US=> NYj0Z2pjW0GQR1XS
SCH NHvXNGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XRWmlEPTB;OU[uN|g4PyEQvF2= MYnTRW5ITVJ?
NCI-H1792 NYPqNIN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PkcGlEPTB;OU[uPFk6OiEQvF2= NHvLNFhUSU6JRWK=
NCI-H2029 MlrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvqfnNWUUN3ME25Ok46PTZ4IN88US=> MnPnV2FPT0WU
SW684 M2XsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LZ[2lEPTB;OUiuOlY2PCEQvF2= NGLwOm5USU6JRWK=
NCI-H209 NWfJb3FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTFyMD6xNlEh|ryP MXLTRW5ITVJ?
HLE NHTRO|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7GTWM2OD1zMEWuNlgzKM7:TR?= NELZR4RUSU6JRWK=
GOTO NGHDclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnyWIV3UUN3ME2xNFcvPzd5IN88US=> MWTTRW5ITVJ?
NCI-H1793 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH5TWM2OD1zMEmuNlgh|ryP NWnhOVRsW0GQR1XS
D-392MG MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFzNz6zPVgh|ryP MYDTRW5ITVJ?
SW1990 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrzTWM2OD1zMkCuPVUyKM7:TR?= MUPTRW5ITVJ?
ML-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rV[mlEPTB;MUKxMlY4PiEQvF2= NEjufINUSU6JRWK=
NCI-H2452 Mn7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\5bIg{UUN3ME2xNlIvOjFizszN MoO4V2FPT0WU
SK-MEL-30 M2KxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS5Tno4UUN3ME2xNlMvOjR2IN88US=> M1LVU3NCVkeHUh?=
SN12C M2j3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLaTWM2OD1zMkSuNVc3KM7:TR?= NUDKWJpmW0GQR1XS
NCI-H1770 NUfUbVM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moe3TWM2OD1zMkWuOVE1KM7:TR?= MUDTRW5ITVJ?
SF268 Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zUOWlEPTB;MUK2MlE2QCEQvF2= NUD5RpppW0GQR1XS
BALL-1 MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIqzXndKSzVyPUGyOk4zOyEQvF2= MXHTRW5ITVJ?
COLO-679 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{KyUGlEPTB;MUK2Mlc2OyEQvF2= MYjTRW5ITVJ?
A2780 MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS2VVJKSzVyPUGyPE46QDhizszN NXW0VHdCW0GQR1XS
NCI-H1651 M4TyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIridGNKSzVyPUGzNU4zPDNizszN M3jyRnNCVkeHUh?=
NCI-H2087 NWW3cIN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHVTWM2OD1zM{GuOFg{KM7:TR?= M{T5XXNCVkeHUh?=
U-87-MG NHLUT5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPJTWM2OD1zM{OuOlA1KM7:TR?= NXPLV4FuW0GQR1XS
LB2518-MEL M2XZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT6TWM2OD1zM{WuPVk{KM7:TR?= NF74XItUSU6JRWK=
HCT-116 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUS2cZBDUUN3ME2xN|cvOjF5IN88US=> NIHRfpZUSU6JRWK=
Ca9-22 M{TtXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLxOVBlUUN3ME2xN|kvQDN|IN88US=> NHrifXBUSU6JRWK=
COR-L88 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTF2Mj6xOEDPxE1? MXTTRW5ITVJ?
CP50-MEL-B MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\1UnJKSzVyPUG0OE42ODFizszN M2Hzd3NCVkeHUh?=
OVCAR-8 NYfGSpluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF2NT62N|Yh|ryP NHvOVG9USU6JRWK=
SK-MEL-3 M1\hV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUi4NIc6UUN3ME2xOFcvQDd6IN88US=> M2LUSHNCVkeHUh?=
GT3TKB NE\pUmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnINHA6UUN3ME2xOFkvQTJ6IN88US=> Mk\nV2FPT0WU
KYSE-450 MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvzWZAzUUN3ME2xOVEvPTN7IN88US=> MlvyV2FPT0WU
CAPAN-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TJ[mlEPTB;MUWzMlA3PCEQvF2= Mn7hV2FPT0WU
BEN MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XEN2lEPTB;MUWzMlkzQCEQvF2= NUHWTVhvW0GQR1XS
NCI-H1304 NVHnZ4p5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L2WWlEPTB;MUW0MlY6PCEQvF2= MkXqV2FPT0WU
KU812 M3fwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF3OD62O|Qh|ryP MkLqV2FPT0WU
Capan-2 NHO5WXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVezSpo3UUN3ME2xOlAvPTV|IN88US=> NV3qdmJ6W0GQR1XS
A673 NU\HeHBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\ofVhKSzVyPUG2NU44ODVizszN MVPTRW5ITVJ?
SAS MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmWyTWM2OD1zNkKuOlc5KM7:TR?= MlzSV2FPT0WU
NY M1TBSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X6TWlEPTB;MU[1MlMyPCEQvF2= MXvTRW5ITVJ?
HCE-4 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\jNmlEPTB;MU[2Mlg1PSEQvF2= MmfEV2FPT0WU
MDA-MB-231 Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHt[m9KSzVyPUG3O{42ODNizszN NIPHd2xUSU6JRWK=
no-10 M2PVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTF5OD6xN|Qh|ryP MUjTRW5ITVJ?
MZ7-mel NFXVNZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVradpJIUUN3ME2xO|gvPDZ5IN88US=> NGLVVVJUSU6JRWK=
NCI-H82 MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHLTWM2OD1zOECuNVY2KM7:TR?= NGHmelVUSU6JRWK=
CAL-72 M1z3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{C4cmlEPTB;MUi1MlA2PCEQvF2= NWm5NJZZW0GQR1XS
NCI-SNU-5 MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTF6Nj64OEDPxE1? MWnTRW5ITVJ?
OVCAR-4 M2W5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnFW5ZUUUN3ME2xPFgvOzN|IN88US=> NWi1RmVWW0GQR1XS
SCC-9 MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTF7MTFOwG0> M1LkWXNCVkeHUh?=
KYSE-150 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vDUWlEPTB;MUmxMlg5QCEQvF2= M{HFb3NCVkeHUh?=
HT-29 NWPjOnZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[0SGlEPTB;MkCxMlIyOiEQvF2= NXLrSGVRW0GQR1XS
COLO-678 NIPLOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLzNXFrUUN3ME2yNFEvPDVizszN NIXZZo9USU6JRWK=
NCI-H650 NHHvVGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILXPWRKSzVyPUKwNk4yODNizszN MlLSV2FPT0WU
HuCCT1 M2XhVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\wUWRKSzVyPUKwOE4zODhizszN NWPCTGFKW0GQR1XS
SW1116 NVHFVI52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\oR5dKSzVyPUKwO{4xPzdizszN NGHEWFlUSU6JRWK=
DBTRG-05MG MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvnTWM2OD1{MEeuPVA6KM7:TR?= M3rt[nNCVkeHUh?=
SW982 M12zO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUKzW5gxUUN3ME2yNFcvQTR6IN88US=> MX3TRW5ITVJ?
RCM-1 NFzkdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJzND63OlIh|ryP M13oOHNCVkeHUh?=
COLO-320-HSR MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13FS2lEPTB;MkG2MlEzPSEQvF2= NHyzPHhUSU6JRWK=
KNS-42 MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\VSJFKSzVyPUKxOk42PzRizszN NEjjR|lUSU6JRWK=
C2BBe1 M4ize2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3STWM2OD1{M{GuPVA2KM7:TR?= M3nD[nNCVkeHUh?=
CCRF-CEM NEHC[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXaXndiUUN3ME2yOFMvPzl3IN88US=> MV3TRW5ITVJ?
SH-4 M1K4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTJ2Nj6wPUDPxE1? NFHKNGtUSU6JRWK=
LS-1034 NFHYVXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjPTWM2OD1{NE[uNlY3KM7:TR?= MlK1V2FPT0WU
NCI-H2347 NHr0d49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TmSWlEPTB;MkS3MlcyOyEQvF2= MV7TRW5ITVJ?
RPMI-8866 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3lTWM2OD1{NEmuNlch|ryP M1jQUnNCVkeHUh?=
GAK NX:2WI9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoftTWM2OD1{NUOuNFAzKM7:TR?= M{WwSnNCVkeHUh?=
NB6 NWG5TnM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\kUGlEPTB;MkewMlEh|ryP NH\oe4NUSU6JRWK=
COLO-680N NWHJSndkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJ5Mj61Nlch|ryP MWnTRW5ITVJ?
RERF-LC-MS MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDBPYZVUUN3ME2yO|YvODB5IN88US=> NX7HR2xIW0GQR1XS
TGBC11TKB NGXEOZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4T0OWlEPTB;Mke4MlE4QCEQvF2= NVjmfopSW0GQR1XS
C8166 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJ5OD61NFYh|ryP MYDTRW5ITVJ?
HDLM-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJ7ND60NFkh|ryP M1HuW3NCVkeHUh?=
IGR-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJ7NT62OVkh|ryP NFPIe5BUSU6JRWK=
FADU M3PKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Tu[2lEPTB;Mkm3MlUyKM7:TR?= MoXIV2FPT0WU
L-428 MmW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXeyfVdFUUN3ME2yPVcvPjF4IN88US=> MnHOV2FPT0WU
LU-65 NW\ydWkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTNyND6zNkDPxE1? M{HQWHNCVkeHUh?=
HEL MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTNyOT65PFMh|ryP NHXReIZUSU6JRWK=
NCI-H810 M{HFRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTNzMD61O{DPxE1? NYCzRWQ{W0GQR1XS
C3A MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfXeFAyUUN3ME2zNVEvQDB{IN88US=> MVfTRW5ITVJ?
NCI-H630 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTN|Mj6yPVQh|ryP Ml\FV2FPT0WU
KP-N-YN NYTJNGJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTN2MT6xNlMh|ryP NG\SPGFUSU6JRWK=
MOLT-13 M{HyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\ubFdKSzVyPUO0Nk4{OjZizszN M1PTe3NCVkeHUh?=
NCI-H1993 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfibG5jUUN3ME2zOFIvOzZ3IN88US=> M4rEOnNCVkeHUh?=
BE-13 NEnuN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXMU4pKSzVyPUO0OE4yPjdizszN M3\lOHNCVkeHUh?=
IST-SL1 MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TiUWlEPTB;M{S3MlQxOSEQvF2= NH\vdIRUSU6JRWK=
TE-9 NX3vXmlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTN4Mz61PFkh|ryP MUfTRW5ITVJ?
LU-135 NGTVVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTmTWM2OD1|NkeuNFM2KM7:TR?= MUTTRW5ITVJ?
T84 NIPRTJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HJemlEPTB;M{e0MlcyOiEQvF2= NGHzTIRUSU6JRWK=
K-562 MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjseHF6UUN3ME2zPFMvOzZizszN NEj4ZnBUSU6JRWK=
SBC-5 NWPSR5oyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTN6Nj65PFUh|ryP NFf4fmRUSU6JRWK=
NB17 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTN7Mj61PVYh|ryP NWXNdJZxW0GQR1XS
NCI-H2052 NVjBO5JVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV22VIJMUUN3ME2zPVgvPDd{IN88US=> MnvWV2FPT0WU
HCC38 M2W4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTRyMT61PVMh|ryP NYnRPHI{W0GQR1XS
NCI-H69 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTlTWM2OD12NEGuNFg{KM7:TR?= NV72N2NCW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

Protocol

Kinase Assay:[4]
+ Expand

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
Cell Research:[2]
+ Expand
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • Concentrations: 0, 0.3, 1 and 3 μM
  • Incubation Time: 72 or 96 hours
  • Method: MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • Formulation: Formulated in 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL (29.14 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 15% Captisol 17 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.39
Formula

C25H21N5O.2HCl

CAS No. 1032350-13-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01306045 Recruiting Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Carcinoma, Thymic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 21, 2011 Phase 2
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Active, not recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID